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Abstract Parkinson’s disease (PD) is a progressive neuro-
degenerative disorder affecting ∼1 % of people over the age
of 65. Neuropathological hallmarks of PD are prominent
loss of dopaminergic (DA) neurons in the substantia nigra
and formation of intraneuronal protein inclusions termed
Lewy bodies, composed mainly of α-synuclein (αSyn).
Missense mutations in αSyn gene giving rise to production
of degradation-resistant mutant proteins or multiplication of
wild-type αSyn gene allele can cause rare inherited forms of
PD. Therefore, the existence of abnormally high amount of
αSyn protein is considered responsible for the DA neuronal
death in PD. Normally, αSyn protein localizes to presynap-
tic terminals of neuronal cells, regulating the neurotransmit-
ter release through the modulation of assembly of soluble N-
ethylmaleimide-sensitive factor attachment protein receptor
complex. On the other hand, of note, pathological examina-
tions on the recipient patients of fetal nigral transplants
provided a prion-like cell-to-cell transmission hypothesis
for abnormal αSyn. The extracellular αSyn fibrils can in-
ternalize to the cells and enhance intracellular formation of
protein inclusions, thereby reducing cell viability. These
findings suggest that effective removal of abnormal species
of αSyn in the extracellular space as well as intracellular
compartments can be of therapeutic relevance. In this re-
view, we will focus on αSyn-triggered neuronal cell death
and provide possible disease-modifying therapies targeting
abnormally accumulating αSyn.
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DLB Dementia with Lewy bodies
DMT1 Divalent metal transporter 1
Dnmt1 DNA methyltransferase 1
ER Endoplasmic reticulum
GCase Glucocerebrosidase
GDNF Glial cell line-derived neurotrophic factor
HDAC Histone deacetylase
Hsc70 Heat shock cognate 70
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ROS Reactive oxygen species
SN Substantia nigra
SNAP-25 Synaptosomal-associated protein of 25 K
SNARE Soluble N-ethylmaleimide-sensitive factor
attachment protein receptor
SNpc Substantia nigra pars compacta
TH Tyrosine hydroxylase
UCH-L1 Ubiquitin carboxy-terminal hydrolase-L1
VPA Valproic acid
Introduction
Parkinson’s disease (PD) is an age-related and the second
most common neurodegenerative disorder beyond Alz-
heimer’s disease [1]. Clinical manifestation of PD is typical
movement abnormalities that include resting tremor, rigidity,
bradykinesia/akinesia, and postural instability. Neuropatho-
logical hallmarks in PD brains are (1) a prominent loss of
dopaminergic (DA) neurons in the substantia nigra (SN) pars
compacta (SNpc) projecting into the caudate/putamen (collec-
tively called as striatum), and (2) formation of protein inclu-
sions termed Lewy bodies and Lewy neurites that can be
found in neuronal somas and processes, respectively. These
aggregates are composed mainly of α-synuclein (αSyn) pro-
tein [2, 3]. Severe deprivation of striatal dopamine in PD can
most effectively be treated with oral administration of dopa-
mine precursor levodopa, whereas a long-term and pulsatile
treatment with levodopa gradually induces adverse involun-
tary movements such as motor fluctuations and dyskinesias
[4]. On the other hand, neurosurgical procedures including
deep brain stimulation can partially normalize neuronal activ-
ities that have been agitated by the loss of the nigrostriatal DA
pathway [5]. However, there have been no therapeutic options
available that can reverse or even retard the progression of the
disease, and such treatments are urgently required. To date,
numerous efforts have been concentrated to elucidate the
molecular mechanisms underlying the DA cell death in PD.
In this article, we will review the relationship between abnor-
mal αSyn and neuronal cell death. Several key molecules that
can modulate the αSyn-induced neuronal death have hitherto
been identified and investigated in αSyn-related animal mod-
els. We will also discuss such neuroprotective remedies for
potential clinical interventions in PD (summarized in Fig. 1).
Neuronal Cell Death in PD Brains: Apoptotic
or Non-apoptotic?
The way in which DA neurons die is the principal enigma in
the field of PD research. In neurodegenerative environ-
ments, neurons die through distinct fashions that are
distinguished by morphological features: (1) apoptosis
(known as type 1 cell death) [6–16], (2) autophagy (type 2
cell death) [9–11], and (3) necrosis (type 3 cell death) or
“necroptosis” [12–16]. Apoptosis is evolutionally conserved
cell-suicide mechanism indispensable for fundamental bio-
logical processes such as normal development, elimination
of malignant neoplasms, and establishment of neuronal cir-
cuitry [6]. The morphologic features of apoptosis include
nuclear and cytoplasmic condensation, internucleosomal
DNA cleavage, and packaging of the dying cell into apo-
ptotic bodies that are engulfed by phagocytes, preventing
release of intracellular components [7]. Pathogenic apopto-
sis cascade can be induced by (1) mitochondrial damage that
involves B cell lymphoma 2 (Bcl-2) family proteins, apo-
ptotic protease-activating factor 1 (apaf-1), and the cysteine
proteases caspases (referred to as intrinsic pathway); and (2)
agonistic ligands of death receptors such as tumor necrosis
factor α (TNFα), Fas ligand (FasL), and TNF-related
apoptosis-inducing ligand (TRAIL), which promote activa-
tion of caspase-8 inside the cell (extrinsic pathway) [10].
The involvement of apoptotic cascade in DA neuronal death
has been controversial in PD [17–25]. We and other groups
have previously reported the positive staining of DA neurons
in PD for terminal deoxynucleotidyl transferase dUTP nick
end labeling (TUNEL) and chromatin condensation, which is
the typical process seen in apoptotic cell death [17, 21, 22].
However, other groups found no signs of apoptosis in the
nigral DA neurons, regardless of disease duration, severity,
drug treatment, and age of the patient [19, 20]. Using electron
microscopy, Anglade et al. [18] showed the presence of con-
densed chromatin in the nucleus of neuromelanin-containing
neurons and engulfment of apoptotic bodies in glial cells.
Importantly, they also observed cells displaying the features
of autophagic degeneration, implying that apoptosis may not
be the sole form involved in DA neuronal death [18].
Autophagy is an evolutionally conserved mechanism for
a bulk degradation of cellular components, including pro-
teins and organelles, and serves as a cell survival mecha-
nism during nutrient deprivation [9]. There exists a complex
crosstalk between apoptosis and autophagy [10]. Common
upstream signals sometimes result in combined autophagy
and apoptosis at the single cell level. In other instances, the
cell dictates autophagy or apoptosis in a mutually exclusive
manner. Under certain circumstances, autophagy allows
cells to adapt to stress, thereby avoiding apoptotic cell death,
e.g., a harmful αSyn can be degraded by autophagic path-
way (see below). By contrast, massive autophagy induces
alternative cell death pathway that is called autophagic cell
death (ACD) [9, 10]. ACD is characterized by the presence
of autophagic vacuoles (autophagosomes), which can be
identified as double-membraned vesicles, and autophagoly-
sosomes, which arise from the fusion of autophagosomes
and lysosomes and are defined by a single membrane, in
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dying cells [9, 10]. On the other hand, Kroemer and Levine
[11] indicated that the term ACD may be a misnomer
because that is, in many cases, cell death “with” autophagy
rather than cell death “by” autophagy. They emphasized that
the autophagic process is not the executioner of cell death,
or rather, cytoprotective response under pro-apoptotic con-
dition [11].
Energy depletion is a potent trigger of necrosis [13].
Morphologically, necrosis is characterized by extensive vac-
uolation of the cytoplasm, mitochondrial swelling, dilatation
of the endoplasmic reticulum (ER) and nuclear membrane,
condensation of chromatin into small, irregular, and circum-
scribed patches, and plasma membrane rupture. Necrotic
cells are lysed and do not fragment into discrete corpses as
their apoptotic counterparts do. As a consequence, cellular
contents are liberated into the extracellular space, which
might precipitate damage to neighboring cells and evoke
inflammatory responses [13, 15]. Necrosis has traditionally
been considered merely as an accidental, uncontrolled form
of cell death that only occurs in pathological conditions.
Also, apoptosis has long been believed the sole form of
programmed cell death (PCD). However, accumulating ev-
idence uncovered another route of PCD, a programmed
necrosis termed necroptosis [reviewed in 14, 15]. While
several articles have suggested the occurrence of the “non-
apoptotic PCD” during neurodegenerative processes [12,
14, 15, 26, 27], there have been a limited number of reports
documenting the necrotic cell death in PD brains. This
might in part be attributed to a methodological difficulty to
dissect necrotic cell explosion in the postmortem brain tis-
sues. It is known that necroptosis is triggered by ligation of
death receptors with TNFα, FasL, and TRAIL, the same
Fig. 1 Schematic representation of molecular events and potential
therapeutic targets associated with abnormal αSyn in PD. The molec-
ular events that are reduced in PD and/or potentially neuroprotective,
or considered to be neurotoxic, are shown in blue, or red arrows and
inhibitory lines, respectively. Accumulation of αSyn oligomer, which
can be modulated by several post-translational modification(s) of
αSyn, leads to reduced neuronal cell viability by inhibiting ER-Golgi
trafficking, autophagy, and/or proteasome. Mitochondrial translocation
of αSyn induces production of ROS and RNS, further enhancing
oxidative/nitrosative modification of αSyn. Oligomerized αSyn spe-
cies can also be secreted into extracellular space, which might induce
inflammatory glial reactions, pore formation on plasma membrane, or
transmission to the neighboring neuronal cells to promote Lewy for-
mation and/or cell death. These neurotoxic events can be ameliorated
by several ways as indicated (also see the main text)
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ligands that activate apoptosis [14, 15]. A death domain-
containing kinase receptor-interacting protein 1 (RIP1) and
RIP3 are required to dictate necroptotic pathway. Caspase-
8 inactivates RIP1 and RIP3 by proteolytic cleavage and
initiates the pro-apoptotic caspase activation cascade [15].
By contrast, inhibition of caspase-8 results in execution of
the programmed necrosis in primary DA cultures [16]. A
small molecule inhibitor of necroptosis, necrostatin-1, atten-
uated RIP1 kinase activity [28] and prevented glutamate-
induced hippocampal neuronal cell death [29]. It needs
further explorations to determine the involvement of nec-
roptosis in DA neuronal degeneration in PD.
Physiological Functions of αSyn
αSyn is a neuronal protein of 140 amino acids and normally
localized to presynaptic terminals. The exact physiological
function of αSyn remains yet defined, but several works
have implicated its role in dopamine biosynthesis, synaptic
plasticity, and vesicle dynamics [1, 30–32]. Indeed, αSyn
directly binds to vesicle-associated membrane protein 2
(VAMP2; also called as synaptobrevin-2) and promotes
assembly of soluble N-ethylmaleimide-sensitive factor at-
tachment protein receptor (SNARE) complex through a
nonclassical chaperone activity [33]. Orchestration of as-
sembly/disassembly of SNARE complex is essential for
the regulation of neurotransmission. Recent studies have
implicated presynaptic dysfunction to be an initial event of
neurodegeneration [34]. A presynaptic protein cysteine-
string protein-α (CSPα) also promotes SNARE complex
assembly through the formation of chaperone complex with
heat shock cognate 70 (Hsc70) and the small glutamine-rich
protein SGT [35, 36]. The CSPα-Hsc70-SGT complex binds
directly to synaptosomal-associated protein of 25 kDa
(SNAP-25), whereby promoting SNARE complex formation
[36]. Depletion of CSPα in mice represents decreased level of
SNAP-25 and corresponding reduced assembly of SNARE
complex [36]. Intriguingly, the CSPα-knockout mice show a
rapidly progressive neurodegeneration and premature death,
both of phenotype counteracted by transgenic expression of
αSyn [37]. On the other hand, increased expression of αSyn
in the absence of overt cell toxicity markedly inhibited
neurotransmitter release, which was attributed to a perturbed
synaptic vesicle density at the active zone, due to a defective
reclustering of synaptic vesicles after endocytosis [38]. In
another study, overexpressed αSyn indirectly inhibited
SNARE-mediated exocytosis by sequestering arachidonic
acid, which upregulates syntaxin and enhances its engagement
with SNARE complex [39]. The opposing actions of αSyn
implicate that a tight regulation of subcellular level and distri-
bution of αSyn is indispensable for the intrinsic functions of
neuronal cells.
Pathogenic Roles of αSyn in PD
αSyn is one of the most extensively studied proteins in PD
research [30–32, 40] (Fig. 1). The gene encoding αSyn
(SNCA) is mutated in rare inherited forms of PD, resulting
in amino acid substitutions (A53T [41], A30P [42], or E46K
[43]; classified as PARK1), or multiplication of its allele
(PARK4) [44, 45]. Moreover, αSyn is a major component of
Lewy bodies and Lewy neurites found in sporadic cases [2,
3]. Therefore, the presence of abnormally high levels of
αSyn protein due to unbalanced production and/or degrada-
tion is thought to trigger DA neuronal death in both familial
and sporadic cases of PD (Fig. 1). Single nucleotide poly-
morphisms in the 5′-promoter and 3′-flanking regions of
SNCA gene that influence αSyn protein level are associated
with susceptibility to idiopathic PD [46–48]. Furthermore,
genome-wide association studies identified SNCA as a com-
mon risk factor for PD [49, 50]. Recent two studies uncov-
ered epigenetic regulation of SNCA gene expression.
Reduced methylation in CpG islands at intron 1 of SNCA
that leads to increased protein production was evident in the
SN of sporadic patients with PD [51, 52]. Desplats et al. [53]
showed reduction of nuclear level of DNA methyltransfer-
ase 1 (Dnmt1) and DNA methylation in human postmortem
brains affected with PD and dementia with Lewy bodies
(DLB). Physical association of αSyn with Dnmt1 might me-
diate the retention of Dnmt1 in the cytoplasm, which results in
hypomethylation of DNA [53]. However, overexpressed
αSyn protein sometimes functions as a neuroprotective mol-
ecule in cell types other than DA neurons [37, 54–56]. Also, a
recent report indicated protective function of physiological
level of αSyn in DA cells. In that study, αSyn was found to
reduce p300/CBP level and its histone acetyltransferase activ-
ity, whereby suppressing the NFκB-mediated transcriptional
expression of pro-apoptotic protein kinase Cδ [57]. Oxidative
modification of αSyn by dopamine metabolites is considered
responsible for the selective vulnerability to DA neurons [55,
58]. Dopamine-modified αSyn tends to form protofibrillar
intermediates but not large fibrils [58]. Such “oligomeric”
αSyn is supposed the real criminal in DA neuronal toxicity
[59–66]. On the other hand, a recent important finding indi-
cated that endogenous normal αSyn forms a helically folded
tetrameric structure of 58 kDa in neuronal and non-neuronal
cell lines, brain tissue, and human red blood cells [67]. The
tetrameric αSyn had high lipid-binding capacity and little or
no propensity for amyloid-like aggregation. They proposed
that destabilization of the tetramer precedes the misfolding
and aggregation of αSyn in pathogenic conditions with PD
and other α-synucleinopathies [67]. Another group also indi-
cated that bacterially produced αSyn forms a stable tetramer
[68] (To avoid misconceptions, hereafter, the nomenclature
“oligomer” will be applied for the toxic species of αSyn
formed in the diseased situations).
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A 22-kDa O-glycosylated form of αSyn (αSp22) is des-
tined for proteasomal degradation by receiving polyubiqui-
tin moieties through the action of E3 ligase parkin, which is
linked to a recessively inherited young-onset PD, PARK2
[69, 70]. Overexpression of wild-type or familial PD-linked
mutant of αSyn in cell culture impairs proteasome activity
and induces apoptosis or ACD, depending on the experi-
mental conditions [71–75]. Soluble oligomeric αSyn im-
paired proteasome activity and likely impeded access of
other proteasomal substrates [76, 77]. αSyn is degraded
not only via ubiquitin-proteasome system but also autoph-
agy [78, 79]. Both macroautophagy and chaperone-
mediated autophagy (CMA) are involved in the clearance
of accumulating αSyn [80]. Overexpressed wild-type αSyn
compromised macroautophagy by inhibiting Rab1a [81],
and pathogenic mutant and dopamine-modified αSyn pre-
vented their own degradation and that of other substrates in
CMA [82, 83]. As a result, DA cells harboring abnormal
αSyn are sensitized to degenerative stimuli.
The majority of cellular source of energy is produced in
mitochondria in the form of ATP. Because of the electrons
being transported along the respiratory chain to potentiate
mitochondrial intermembranous proton gradient, the prereq-
uisite for oxidative phosphorylation, this organelle can in-
trinsically be a primary source of reactive oxygen species
(ROS). A number of studies have demonstrated mitochon-
drial dysfunction and oxidative (and nitrosative) stresses
linked to neuronal cell degeneration in PD [reviewed in
84]. This is well illustrated in an animal model of PD
generated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyri-
dine (MPTP), which inhibits complex I in the electron
transport system [85, 86]. αSyn protein has a non-
canonical mitochondrial targeting sequence at its N-
terminus and is indeed translocated to mitochondria in hu-
man fetal DA neuronal culture and postmortem normal brain
tissues [87]. The mitochondrial αSyn accumulation is en-
hanced in PD brains. αSyn interacts with complex I and
interferes with its function, promoting the production of
ROS [87]. Particularly, superoxide radical rapidly reacts
with nitric oxide to yield highly reactive peroxynitrite anion
and ensuing reactive nitrogen species (RNS) [84]. ROS/
RNS covalently modify lipids, nucleic acids, and proteins.
αSyn can be modified with these compounds, augmenting
the formation of toxic oligomeric αSyn (see below) [88].
Previous studies have implicated an increased iron level
in the SN of postmortem brains of idiopathic PD and parkin-
deficient PARK2 patients [89–91]. In MPTP-treated hemi-
parkinsonian monkeys, we and another group reported that
DA cell death preceded iron accumulation [92, 93], suggest-
ing that the elevation of iron may be a secondary event in
nigral degeneration. On the contrary, several recent studies
indicate that intraneuronal iron overload can be a primary
cause of DA cell death in part through enhancing the
formation of toxic radicals by Fenton reaction [94–96]. An
iron transporter, divalent metal transporter 1 (DMT1), is
upregulated and contributes to nigral DA neuronal death in
MPTP and 6-hydroxydopamine rodent models of PD [94,
95]. Importantly, parkin regulates uptake of iron via degra-
dation of DMT1 in ubiquitin-proteasome system [96]. These
results suggest that DMT1-mediated iron overload can
cause DA cell loss in parkinsonian brains. Iron promotes
aggregation of αSyn protein [97, 98], and formation of
pore-forming toxic oligomer species [99]. Moreover,
DMT1-mediated cell death was aggravated in the presence
of mutant αSyn as a result of excessive autophagic activity
[100].
Recent studies revealed the association of Gaucher dis-
ease, the lysosomal storage disorder, with αSyn pathology
[101–105]. Gaucher disease is caused by mutations in the
gene encoding lysosomal protein glucocerebrosidase
(GCase) that also increase the risk for PD and DLB
[reviewed in 105]. A direct physical interaction between
GCase and αSyn that prefers lysosomal acidic condition
has been demonstrated [102]. In another study, importantly,
glucosylceramide, which is the substrate of GCase and
accumulated in Gaucher disease brains, directly influenced
amyloid formation of αSyn by stabilizing soluble oligomer-
ic intermediates [103]. The oligomeric αSyn in turn
inhibited intracellular trafficking of GCase and decreased
lysosomal GCase function. Such bidirectional effects of
αSyn and GCase form a positive feedback loop that may
lead to a self-propagating disease [103]. Genetic mouse
model of Gaucher disease exhibited αSyn accumulation in
the SN, cortex, or hippocampus [103, 104], and adeno-
associated viral (AAV) vector-mediated delivery of GCase
ameliorated pathological and behavioral aberrations in the
Gaucher mice [104].
Prion-Like Cell-to-Cell Transmission of αSyn
In the last 20 years, more than 300 patients with PD have
received striatal transplantation of midbrain tissues that were
isolated from aborted fetuses [106, 107]. Many of these
patients experienced a transient improvement of motor
symptoms [106, 107], while severe off-phase dyskinesia
remains a major concern [108–110]. On the other hand,
intriguingly, more than a decade after the fetal transplanta-
tion, Lewy-like inclusions were depicted to be present in the
surviving DA cells in the grafts [111, 112]. These findings
led to the current provocative hypothesis that αSyn protein
itself might transmit from neuron to neuron like as prion
proteins, whereby spreading the pathologies in the brains of
PD and other α-synucleinopathies [113–115].
Indeed, αSyn and its oligomeric forms are localized in
the lumen of vesicles in differentiated neuronal cells and rat
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synaptosomal preparations, and secreted via non-classical
ER/Golgi-independent exocytosis like as a part of the nor-
mal life cycle of this protein [116]. The intravesicular αSyn
was found more prone to aggregation compared with cyto-
solic αSyn [116]. Another group showed that soluble mo-
nomeric and oligomeric αSyn were externalized via the
vesicles that have characteristic hallmarks of exosomes in
a calcium-dependent manner, and significantly reduced cell
viability [117]. Danzer et al. [63] showed that different
species of extracellular αSyn oligomers can exert distinct
effects on cells; some oligomeric αSyn induced cell death
by presumably pore-forming mechanism, and the other form
of oligomer directly entered the cell and enhanced aggrega-
tion of αSyn. They proposed that heterogeneous popula-
tions of oligomeric forms coexist in equilibrium [63]. A
solution structure of the pore-forming αSyn oligomer has
been determined by small angle X-ray scattering [65]. On
the other hand, cationic liposome-mediated forced transduc-
tion of exogenously produced fibrils of αSyn could seed the
intracellular formation of Lewy-like inclusion in cultured
cells [118, 119]. Furthermore, several groups reported that
the extracellular αSyn can be uptaken by cells through
endocytotic mechanism, and the internalized αSyn en-
hanced aggregation of (endogenous or overexpressed) αSyn
and neuronal cell death [120–122]. Importantly, Mougenot
et al. [123] demonstrated prion-like propagation of αSyn
pathology in αSyn-transgenic mice. Brain homogenates
from old αSyn-transgenic mice, which display motor clini-
cal signs and contain insoluble Ser129-phosphorylated
αSyn, were intracerebrally inoculated to young αSyn-
transgenic mice. This triggered an early onset of character-
istic motor signs and a prominent formation of inclusions
that contain Ser129-phosphorylated αSyn, compared with
uninoculated αSyn-transgenic mice or mice inoculated with
brain homogenate from young healthy αSyn-transgenic
mouse [123]. In that experiment, αSyn-null mice showed
no abnormalities when inoculated with the brain homoge-
nate of old disease-state αSyn-transgenic mice, indicating
the crucial role for the presence of (pre-abnormal) αSyn in
the host brain [123]. Extracellular αSyn is also capable of
inducing microglial activation [124] and pro-inflammatory
cytokine release from astrocytes [125] that may enhance
neuronal toxicity. Accordingly, removal of extracellular
αSyn species may be relevant to disease modification. Vac-
cination or passive immunization targeting the overloaded
αSyn has successfully cured mice from neuronal degenera-
tion (see below) [126, 127].
αSyn-Transgenic Animals
αSyn-transgenic models have been generated in mice
[reviewed in 31, 128–130] and other organisms including
nematode Caenorhabditis elegans [131–133] and fruit fly
Drosophila melanogaster [134, 135]. Nematode models of
αSyn overexpression exhibited neuronal or dendritic loss of
DA cells and corresponding behavioral deficits [131–133].
Drosophila models of αSyn overexpression show adult-
onset loss of DA neurons and locomotor dysfunction [134,
135]. These invertebrate models well recapitulate several
key features of human PD and are relevant for comprehen-
sive genetic analyses and drug screening towards elucidat-
ing the molecular pathogenesis and developing therapies for
α-synucleinopathies [131–135].
On the other hand, a single transgenic expression of wild-
type or familial PD-associated αSyn mutant in mice hardly
represents a progressive loss of DA cells in the SNpc [31,
128–130]. Masliah et al. [136] reported the decrease of the
striatal DA terminals and corresponding motor impairment
induced by the overexpression of wild-type αSyn under the
regulatory control of human platelet-derived growth factor-
β (PDGF-β) promoter. Thereafter, several lines of αSyn-
transgenic mice were generated and displayed severe move-
ment disorders, loss of neuronal cells other than DA ones,
and/or synaptic dysfunction before overt neuronal loss. In
the transgenic mice of αSyn A53T mutant driven by the
mouse prion promoter, which were originally reported by
Lee et al. [137], Martin et al. [138] found that neocortical,
brainstem, and motor neurons developed Lewy-like intra-
neuronal inclusions, axonal degeneration, and mitochondrial
damage, as well as p53- and caspase-3-mediated apoptotic
death. This report provided a mechanistic insight into the
severe movement disorder of the αSyn A53T-transgenic
mice. Sotiriou et al. [140] recently showed that the mouse
prion promoter-αSyn A53T-transgenic mice, originally
reported by Giasson et al. [139], had selective vulnerability
for noradrenergic systems in the spinal cord, olfactory bulb
(OB), and striatum in an age-dependent manner, while DA
cells in the SN and noradrenergic cells in the locus coeruleus
were not affected [140]. Lim et al. [141] generated inducible
line of αSyn-transgenic mice with a tet-off system and the
calcium/calmodulin-dependent protein kinase IIα
(CaMKIIα) promoter, in which A53T mutant can be condi-
tionally expressed in neuronal cells mainly in the cortex and
hippocampus, to model human DLB. αSyn pathology and
age-dependent neuronal cell loss was observed in cortical
and hippocampal areas that resulted in memory impairment.
Drug-induced suppression of αSyn transgene partially
cleared pre-existing αSyn pathology and reverted defects
in presynaptic proteins including synaptophysin, CSPα,
synaptotagmin, SNAP-25, and syntaxin, and corresponding
memory functions [141]. These results emphasize that tar-
geted removal of αSyn pathology can reverse cognitive
decline in DLB.
On the other hand, oxidation and nitration of αSyn indu-
ces the formation of stable dimers and oligomers through
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intermolecular dityrosine cross-linking [88]. αSyn pos-
sesses four tyrosine residues at positions 39, 125, 133, and
136 and lacks cysteine. When cysteine was substituted for
tyrosine 39 and 125, these mutants increased intracellular
inclusions and induced apoptosis in a rat DA cell line [142].
They indicated that cross-linking at critical positions in αSyn
molecule can increase dimer formation, and accelerate protein
aggregation and cellular toxicity of αSyn [142]. αSyn-
transgenic mice carrying Y39C substitution under the murine
Thy1 promoter were then generated and analyzed [143]. The
mice showed age-dependent formation of αSyn oligomer and
aggregate, progressive apoptotic cell loss in the cortex, and
motor and cognitive deficits similar to DLB. Midbrain DA
neurons and spontaneous locomotor activity were not affected
in the αSyn Y39C-transgenic mice [143].
The murine prion promoter-αSyn-transgenic mice carry-
ing E46K mutation, initially reported to cause PD and DLB
[43], displayed detrimental age-dependent motor impair-
ment, although DA neurons in the SN did not produce αSyn
E46K protein [144]. These animals accumulated intracyto-
plasmic neuronal inclusions of αSyn in the cerebellum and
pons that more closely resemble nigral Lewy bodies in PD
than the previously described transgenic mice of human
A53T αSyn. Intriguingly, phosphorylated tau-positive
inclusions were found in the motor cortex and pons of the
αSyn E46K-transgenic mice [144].
αSyn can be processed by C-terminal truncation in nor-
mal and PD brains [145, 146], and this modification pro-
motes aggregation of αSyn [145–149]. The transgenic mice,
that express C-terminally truncated form of αSyn [αSyn(1–
120)] under the control of rat tyrosine hydroxylase (TH)
promoter on a mouse αSyn-null background, exhibited the
formation of pathological αSyn-positive inclusions in the
SN and OB, reduction of the striatal dopamine levels, and a
progressive reduction in spontaneous locomotion, in the
absence of DA cell death [150]. In the following study, they
investigated the presynaptic SNARE proteins in the striatum
of the αSyn(1–120)-transgenic mice [151]. Synaptic accu-
mulation of αSyn was accompanied by age-dependent re-
distribution of SNAP-25, syntaxin-1, and synaptobrevin-2,
as well as reduced exocytosis of dopamine. A similar redis-
tribution of the SNARE proteins was detected in PD brains
[151]. Of note, Wakamatsu et al. [152] reported a selective
loss of DA neurons in the SNpc of the transgenic mice
carrying human αSyn(1–130). This truncated form of αSyn
further caused reduction of the striatal DA axon terminals
and dopamine level with corresponding reduction of loco-
motor activity, which can be reversed by administration of
levodopa. However, the loss of nigral DA neurons was not
progressive and seemed to occur during embryogenesis
along with the onset of transgene expression [152].
Mutations in leucine-rich repeat kinase 2 (LRRK2) gene
have been linked not only to a dominantly inherited PARK8
[153, 154] but also to sporadic form of PD [155]. The gene
product LRRK2 possesses multiple functional domains in-
cluding GTPase and kinase domains [156, 157]. A com-
monly found mutation, G2019S, increased its kinase
activity, suggesting a gain-of-function mechanism for the
pathogenesis of LRRK2-linked PD [157]. Intriguingly,
LRRK2 accelerated the progression of neuropathology of
αSyn [158]. Lin et al. [158] produced inducible line of
LRRK2- or αSyn A53T-transgenic mice with a tet-off sys-
tem and CaMKIIα promoter, in which the PD-related trans-
gene can be expressed at high-level (LRRK2: about 8- to
16-fold; and αSyn A53T: about 30-fold) in neuronal cells in
the striatum and cortex. While LRRK2 alone did not cause
neurodegeneration, the presence of excess LRRK2 G2019S
exacerbated abnormal accumulation and aggregation of
αSyn A53T, which likely stemmed from the impairment of
microtubule dynamics, Golgi organization, and the
ubiquitin-proteasome pathway. Morphological abnormality
of mitochondria and superoxide production was also pro-
moted in the presence of high amount of LRRK2. In their
αSyn A53T mice, genetic ablation of LRRK2 preserved the
Golgi structure and suppressed the accumulation/aggrega-
tion of αSyn, and then delayed the progression of neuropa-
thology [158]. This study elegantly demonstrated that
suppression of LRRK2 can be a potential therapeutic target
to ameliorate αSyn-induced neurodegeneration. In another
report, by contrast, a single LRRK2-knockout mouse, which
has a normal nigrostriatal DA system, developed accumula-
tion and aggregation of αSyn and ubiquitinated proteins in
the kidneys during aging [159]. This was possibly due to
impairment of autophagy-lysosomal pathway. Furthermore,
the ablation of LRRK2 gene dramatically increased apopto-
tic cell death, inflammatory responses, and oxidative dam-
age in the kidney. These mice implicated that loss-of-
function mutations of LRRK2 may cause cell death via
impairment of protein degradation pathways, which lead to
αSyn accumulation and aggregation [159].
Viral Vector-Mediated αSyn Overexpression Models
PD models have also been generated by viral vector-
mediated overexpression of αSyn in rodents and nonhuman
primates [160–166]. The AAV and lentiviral vectors have
efficient tropism for DA neurons when injected into the SN
and the ability of long-term stable gene expression with low
accompanying cytotoxicity [167, 168]. In rodents, the viral
vector-mediated overexpression of wild-type and familial
PD-associated αSyn mutants can cause a progressive loss
of DA cell bodies with neuritic pathology [160–163]. Rep-
resentative images are shown in Fig. 2. The DA cell death
was accompanied with phosphorylation of αSyn at Ser129
residue and apoptotic cascade with activation of caspase-9
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in our examination [163]. We have also reported that, in the
presence of the PARK5-linked ubiquitin carboxy-terminal
hydrolase-L1 (UCH-L1) I93M mutant in mice, the AAV-
αSyn-induced accumulation of αSyn and apoptotic DA cell
death was enhanced, but not influenced in the absence of
wild-type UCH-L1, indicating that PARK5-linked PD might
be caused by gain-of-function mutation in UCH-L1 [166].
Importantly, Chung et al. [169] found that disturbance of the
proteins relevant to synaptic transmission and axonal trans-
port preceded the AAV-αSyn A53T-induced DA neuronal
loss. It is known that a majority of the virally αSyn-
challenged rodents lacks significant behavioral abnormali-
ties, although they finally exhibit a profound DA neuro-
degeneration [160, 161, 163].
By contrast, adult common marmosets (Callithrix jac-
chus) injected with αSyn-encoding AAV exhibited a severe
neuronal pathology with a significant motor impairment
such as head position bias in a short-term (16-weeks) study
[164]. In a long-term examination for 1 year, the αSyn-treated
monkey displayed behavioral impairments including full body
rotation, head turn bias, and slowed and decreased use of
contralateral hand [165]. These motor abnormalities were
most pronounced in αSyn A53T-transduced group compared
with wild-type αSyn and control GFP groups. About half of
the αSyn A53T monkeys analyzed further developed slips of
contralateral limbs (hand and foot) and persistent head tilts
down on the contralesional side in the later phase [165].
Pathologically, wild-type αSyn-transduced monkeys
exhibited a notably lower density of fibers immunopositive
forαSyn in the caudate and putamen than for GFP in the GFP-
transduced monkeys. The αSyn-containing aggregates were
also found in the striatal fibers. This finding was even more
pronounced in the αSyn A53T group, where only a sparse
network of αSyn-positive fibers was seen in the caudate/puta-
men. In the αSyn A53T group, the ectopic αSyn protein
appeared to have cleared from the SN, and there were fewer
surviving αSyn-positive cell bodies compared with wild-type
αSyn and GFP groups. When the Ser129-phosphorylated
αSyn was examined by immunostaining, some of the neurons
in the SN appeared normal while other cells were atrophic
with shrunken cell bodies or had dystrophic dendrites, some
with beaded aggregations. Interestingly, in several cases, the
Ser129-phosphorylated αSyn-positive staining was localized
to the nucleus (see below) [165]. In the wild-type and A53T
αSyn groups, a substantial loss of TH-positive DA axon
terminals and numerous pathological TH-positive
Fig. 2 AAV vector-mediated expression of foreign gene in mouse
brain. a The AAV vector can be injected stereotaxically into the SN
of mice. b–e Representative images for the AAV vector-mediated
overexpression of human αSyn (hαSyn) or GFP in DA cells. Nigral
sections of the AAV-GFP- (b, d) or AAV-hαSyn-injected mice (c, e)
were immunostained for GFP (GFP; b, d; shown in green) or hαSyn
(c, e; green) and tyrosine hydroxylase (TH; b–e; red; merged with anti-
GFP or hαSyn, yellow). Images for DAPI are also merged (d, e; blue).
Note that the overexpression of hαSyn caused a profound loss of DA
cell bodies with neuritic pathology. The overexpressed hαSyn was
localized to nucleus and cytoplasm in a heterogeneous pattern in the
remaining DA cells, while GFP distributed uniformly. Scale bars: (b,
c) 20 μm and (d, e) 10 μm
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accumulations were found in the striatum, suggesting that
some of the affected but surviving cells were nonetheless
dysfunctional. In the SN, the αSyn A53T-transduced
monkeys showed a clear and consistent DA neurodegenera-
tion in the injected side, which was significantly different
when compared with GFP and wild-type αSyn groups
[165]. The nonhuman primate model of α-synucleinopathy
will be greatly useful for preclinical researches potentially
preventing or retarding the behavioral and pathological pro-
gressions of the disease.
Phosphorylation and Neurotoxicity of αSyn
As described above, αSyn receives several post-
translational modifications in diseased brains. In particular,
Fujiwara et al. [170] found that about 90 % of αSyn proteins
deposited in the brains of α-synucleinopathy are phosphor-
ylated at Ser129 residue. Thereafter, the relationship be-
tween phosphorylation and neuronal toxicity of αSyn has
been investigated. In dopamine-producing cells, rotenone
treatment induced Ser129 phosphorylation of αSyn and
formation of Lewy-like aggregates, with increased apoptotic
cell death through the unfolded protein response [171]. In
another study, increased oxidative stress or proteasomal
inhibition caused significant elevation of soluble and non-
aggregated form of Ser129-phosphorylated αSyn with in-
creased DA cell death [172]. These in vitro studies sug-
gested that Ser129 phosphorylation of αSyn is toxic to DA
cells. Chen and Feany [173] reported that phosphorylation
at Ser129 is essential for αSyn to have neuronal toxicity in a
Drosophila model of PD. The toxicity was abolished by
amino acid substitution S129A that is no longer phosphor-
ylated, and reproduced by S129D that carries a negative
charge mimicking phosphate on serine residue [173]. On
the other hand, phosphoprotein phosphatase 2A (PP2A)
dephosphorylates αSyn at Ser129, and this activity is en-
hanced by carboxyl methylation of the catalytic C subunit of
PP2A [174]. αSyn-transgenic mice raised on a diet supple-
mented with eicosanoyl-5-hydroxytryptamide, an agent that
enhances PP2A methylation, dramatically reduced both
Ser129 phosphorylation and aggregation of αSyn in the
brain [174]. These mice displayed enhanced neuronal activ-
ity, increased dendritic arborizations, and reduced astroglial
and microglial activation, as well as improved motor per-
formance [174].
There exist opposing reports as to the neurotoxicity of the
Ser129-phosphorylated αSyn in the viral vector-mediated
rodent model of αSyn overexpression. Alteration of Ser129
to nonphosphorylated Ala resulted in enhanced [175, 176]
or unchanged toxicity of αSyn [177], and alteration of
Ser129 to a phospho-mimetic Asp resulted in eliminated
[175, 176] or unchanged toxicity of αSyn [177]. These
studies suggest that the Ser129 phosphorylation of αSyn
has, if any, protective effect on DA neurons. We recently
reported that viral vector-mediated delivery of parkin pre-
vented DA neuronal loss induced by a chronic MPTP in
mice [178]. The osmotic minipump-mediated MPTP infu-
sion caused accumulation of the Ser129-phosphorylated
αSyn in DA cells, which was enhanced by overexpression
of parkin, suggesting that the phosphorylation resulted in
reduced toxicity of αSyn [178]. This result is in line with the
report by Lo Bianco et al. [179] who demonstrated that
lentiviral-parkin attenuated αSyn-induced DA cell loss by
increasing the number of the Ser129-phosphorylated αSyn-
positive inclusions in rats. The discrepancy in the neurotoxic
consequence of the αSyn Ser129 phosphorylation makes
difficulties in developing disease-modifying therapies. More
elaborate time-series examinations in primates might be
required to target this post-translational modification.
Prevention of αSyn-Induced Neuronal Cell
Death/Dysfunction
αSyn-induced neuronal cell death and dysfunction can be
targeted by several strategies. Masliah’s group has reported
effective treatment of αSyn-transgenic mice with active and
passive immunization protocols, which enabled clearance of
toxic αSyn in multiple neuronal populations simultaneously
[126, 127]. Passive immunization with a monoclonal anti-
body directed against C-terminus of αSyn (epitope: 118–
126 amino acids of αSyn) that crossed into the central
nervous system ameliorated behavioral deficits and synaptic
abnormalities in αSyn-transgenic mice [127]. Moreover, the
monoclonal antibody reduced the accumulation of calpain-
cleaved and oligomerized αSyn aggregates in neuronal cells
via lysosomal-degradation pathway [127]. They further in-
dicated that lentiviral vector-mediated transduction of beclin
1, a regulator of autophagic pathway, ameliorated the syn-
aptic and dendritic pathology in αSyn-transgenic mice [79].
The reduced accumulation of αSyn induced by the beclin 1
transduction was accompanied by enhanced lysosomal acti-
vation. These studies demonstrated that beclin 1-mediated
autophagy pathway plays an important role in the intracel-
lular degradation of αSyn and may present a novel thera-
peutic target for DLB and PD [79].
A number of studies demonstrated that parkin, PARK2-
associated ubiquitin E3 ligase, protects against αSyn-
induced cell death in vitro. Petrucelli et al. [72] showed that
αSyn A53T-mediated toxicity in primary neuronal culture,
which could be mimicked by the application of proteasome
inhibitor, was reduced by E3 ligase activity of parkin. This
study implicated that parkin and αSyn are linked in a
common pathway associated with selective DA neuronal
cell death. Another group reported that parkin could restore
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the reduced cell viability induced by wild-type αSyn via
activation of calpain [180]. The calpain-mediated cleavage
of accumulated αSyn occurred independently of proteaso-
mal degradation [180]. In Drosophila model of PD, parkin
suppressed DA neuronal death induced by overproduction
of αSyn as well as parkin-associated endothelin receptor-
like receptor (Pael-R) [181]. In rats, we have shown that
AAV vector-mediated parkin delivery ameliorated DA cell
loss induced by overexpression of wild-type αSyn [182].
On the other hand, parkin is known to interact with and
ubiquitinate synphilin-1 [183], which was isolated as αSyn-
interacting protein by yeast two-hybrid screen [184],
through nonclassical K63-linked fashion [185]. Co-
expression of αSyn and synphilin-1 resulted in the forma-
tion of Lewy body-like ubiquitin-positive cytosolic inclu-
sions [183–185], which were found to be cytoprotective
under proapoptotic stimuli [186]. A recent study indicated
that transgenic expression of synphilin-1 attenuated αSyn-
induced cell death in mice [187]. A double-transgenic
mouse for αSyn A53T-mutant and synphilin-1 exhibited
longer lifespan, improved motor performance, and reduced
neuronal degeneration in the brainstem as compared to their
single αSyn A53T-transgenic counterparts. Increased expres-
sion of beclin 1 and enhanced formation of aggresome-like
structures were observed in the double αSyn A53T/synphilin-
1-transgenic mice [187]. On the other hand, αSyn can directly
be modified with small ubiquitin-related modifier (SUMO) at
the positions of lysine 96 and 102 residues [188, 189]. The
sumoylated αSyn showed increased solubility, whereas un-
modified αSyn formed fibrils. Simultaneous substitution of
K96 and K102 to arginine residues, which significantly im-
paired the sumoylation but did not affect the ubiquitination
status of αSyn, was manifested by increased aggregation
propensity and neuronal toxicity in vitro and in vivo [189].
Regulation of αSyn sumoylation may thus have a therapeutic
potential.
We have shown previously that downregulation of SNCA
transcripts by the AAV-mediated transduction of ribozymes
provided rat DA neurons with a resistance to neurotoxin-
induced αSyn accumulation and cell death [190]. Recently,
Junn et al. [191] reported that downregulation of αSyn expres-
sion via microRNA-7 was effective for protection of αSyn
A53T-expressing cells against oxidative stress. MicroRNA-7
was abundantly expressed in neurons in the SN, striatum, and
OB in mice, the most affected areas in PD. Intoxication of mice
with MPTP caused 50 % decrease of microRNA-7 in ventral
midbrain, raising the possibility that the reduction of
microRNA-7 in PDmay cause degeneration of the nigrostriatal
system, likely through upregulating αSyn production [191].
Sirtuin family of the class III NAD+-dependent histone
deacetylases (HDACs) is involved in a variety of biological
processes and several age-associated diseases [192, 193].
One of the family members, sirtuin 1, the mammalian
ortholog of yeast Sir2, is upregulated under the conditions
of caloric restriction and resveratrol treatment, and has a
critical role in cell survival [192, 193]. On the other hand,
sirtuin 2 induces neuronal cell death through its protein
deacetylase activity [194]. The opposing mode of function
is called as yin and yang of sirtuins [195]. A potent inhibitor
of the deacetylase activity of sirtuin 2, AGK2, alleviated
αSyn-induced DA neuronal cell death in primary cell cul-
ture and Drosophila models of PD [194]. In αSyn-
aggregation experiment, where αSyn and synphilin-1 were
co-introduced, AGK2 decreased the number and increased
the size of αSyn aggregates, suggesting that the formation
of large aggregates of αSyn might affect neuronal survival
[194]. On the other hand, αSyn was found localized to the
nucleus of DA neurons in mice that were exposed to neu-
rotoxic herbicide paraquat, and associated with histones in
vitro [196]. Kontopoulos et al. [197] have shown in DA cell
line and Drosophila models that wild-type αSyn, C-
terminally tagged with nuclear localization sequence or
nuclear export sequence, enhanced or attenuated the neuro-
nal toxicity, respectively. The inherited PD-linked A53T or
A30P mutation promoted the nuclear localization of αSyn.
Intranuclear αSyn inhibited histone acetylation and admin-
istration of HDAC inhibitors, sodium butyrate or suberoy-
lanilide hydroxamic acid (SAHA), protected against the
αSyn-induced DA cell loss [197]. Valproic acid (VPA),
another HDAC inhibitor selective for class I and IIa
HDACs, has been clinically used for the treatment of bipolar
mood disorder, schizophrenia, and convulsive seizures [198,
199]. Leng and Chuang [56] reported that VPA induced
upregulation of αSyn through hyperacetylation of histone
H3 in the SNCA promoter region in rat cerebellar granule
cells and cortical neurons. The increased αSyn protein par-
ticipated in neuroprotection against glutamate-induced exci-
totoxicity. By contrast, recent study indicated that VPA
showed neuroprotective effect in rotenone-induced PD
model rats [200]. In the minipump-mediated rotenone rats,
monoubiquitinated αSyn increased its localization into the
nuclei, suggesting that the monoubiquitinated αSyn func-
tions in the nucleus to promote DA neuronal cell death. The
intranuclear translocation of αSyn and subsequent DA cell
death was attenuated by VPA treatment [200].
On the other hand, abnormally accumulating αSyn was
found to induce ER stress via blocking the vesicular traf-
ficking from ER to Golgi network [201]. In genome-wide
screen, Rab guanosine triphosphatase YPT1 (a member of
Rab subfamily that belongs to Ras superfamily) was identi-
fied to modify the cell toxicity of abnormal αSyn and
associate with cytoplasmic αSyn inclusions in yeast cells.
Transgenic expression of Rab1 (the murine YPT1 ortholog)
rescued the loss of DA neuronal cells in Drosophila and C.
elegans models of αSyn overexpression [201]. This re-
search group indicated in the following experiments that
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αSyn disrupts localization of several Rab proteins [202].
Transduction of RAB8A, the human homolog of yeast
Sec4p and a close paralog to Rab1, and another neuron-
specific RAB3A that functions at the synapse were also able
to provide substantial rescue against αSyn-induced DA
neurodegeneration in C. elegans and primary midbrain cul-
ture [202].
Rapamycin is an allosteric inhibitor of mammalian target
of rapamycin (mTOR), an intracellular serine/threonine pro-
tein kinase involved in various cellular processes including
cell growth and proliferation, protein synthesis, and autoph-
agy [reviewed in 203]. Rapamycin has been clinically used
as immunosuppressant drug to prevent the graft rejection
and is now extensively studied as promising anticancer
agents because of its anti-proliferative properties [203].
Recent two reports indicated that systemic treatment with
rapamycin protected DA neurons from death in MPTP
mouse model of PD [204, 205]. The neuroprotective molec-
ular cascade upregulated by systemic rapamycin was dis-
tinct in these two reports. One indicated that rapamycin
blocked mTOR complex 1-induced upregulation of pro-
cell death RTP801 protein, which inactivate mTOR complex
2-mediated phosphorylation of pro-survival Akt kinase
[203, 204]. In the other report, mitochondria-derived ROS
induced permeabilization of lysosomal membranes that
resulted in accumulation of altered mitochondria and unde-
graded autophagosomes [203, 205]. The lysosomal mem-
brane permeabilization also induced ectopic release of
lysosomal proteases cathepsin B and D to the cytosol, which
can cause the digestion of vital proteins or the activation of
additional hydrolases, including caspases. All of these path-
ogenic events, including apoptotic cell death, can be atten-
uated by rapamycin treatment. In particular, rapamycin was
shown to restore impairment of lysosome-mediated clear-
ance of autophagosome, by boosting lysosomal biogenesis
and promoting autophagolysosome formation [203, 205].
αSyn-transgenic mouse model of DLB and PD [136], which
displayed elevation of mTOR, reduction of autophagy-
related protein 7 (Atg7) levels, and the presence of abundant
and abnormal autophagosomes, was also healed with rapa-
mycin [206]. Intracerebral infusion of rapamycin into the
lateral ventricle of αSyn-transgenic mice enhanced clear-
ance of αSyn protein accumulating in neuronal cell bodies
and synapses and redistribution to the axons, through upre-
gulation of autophagy pathway. This study further indicated
lentiviral vector-mediated Atg7 expression resulted in re-
duced accumulation of αSyn and amelioration of associated
neurodegenerative alterations [206].
Neurotrophic factors including glial cell line-derived
neurotrophic factor (GDNF) and its closely related family
protein Neurturin have provided promising therapeutic
effects in various animal neurotoxin models and phase I
clinical trials for PD [reviewed in 207]. However,
surprisingly, AAV or lentiviral vector-mediated GDNF de-
livery did not prevent DA neuronal cell loss induced by the
virally overexpressed αSyn of wild-type or A30P mutant
[208, 209]. The difference in neuroprotective efficacy of
GDNF raises important issues pertinent to the relevance
for the therapeutic use of GDNF and Neurturin in the
patients with PD.
Conclusion
αSyn has a central role in the pathogenesis of PD and other
α-synucleinopathies, and a proper regulation of production,
distribution, modification, and degradation of αSyn is cru-
cial for neuronal functions and viability. Correction of the
impairments in these multiple aspects of αSyn protein in its
life cycle should provide disease modification remedies for
the patients suffering from the devastating neurological
disorders.
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